Euan S. Thomson, PhD, global president of ophthalmic devices at Carl Zeiss Meditec, talks about the “Zeiss Virtual Experience” during the 2020 EURETINA virtual meeting, and how attendees can navigate the booth to find the must-see products Zeiss is highlighting.
Lars Risby, international sales and training manager, Oculus Surgical, discusses how the global pandemic has re-prioritized production lines to enhance sterile product offerings and how the company is working with others in industry to improve overall product lines.
Dr Grazia Pertile, head of the Department of Ophthalmology, Sacrocuore Hospital, Negrar-Verona, Italy, reveals two courses that will be taking place at this year’s EURETINA.
Krysten Williams, head of global marketing and education at Heidelberg Engineering, describes what’s new in multimodal imaging and how Heidelberg plays a role in it, the company’s virtual academy, and they're promoting the “dynamic visualization” of the entire eye.
Hamadi El-Ayari, vice president, sales and marketing at Geuder AG, divulges details about the numerous product introductions the company is planning at the 2020 EURETINA virtual conference.
Prof. Anat Lowenstein of Tel Aviv University, Israel, discusses the innovative moves towards incorporating head-wearable devices in surgical theatres and the importance of improving outcomes in the management of AMD patients with home monitoring, a field particularly noteworthy during the COVID-19 pandemic.
Mehran Nouroozian, Regional Manager at Oertli for the Middle East Region, India, and Turkey at Oertli, shows off the company’s newest product additions during this year's virtual meeting.
Prof. Frank Holz, Chairman of the Department of Ophthalmology at the University of Bonn, Germany, highlights the topics, lectures, symposia and instructional courses that will take place at this year’s virtual EURETINA conference, and gives his insights on the hot topics of the dynamic retina field.
Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.
Agreement would include global rights for investigational treatment, risuteganib, expected to help reverse vision loss due to dry AMD
Interim data update from first cohort using suprachoroidal delivery of RGX-314 expected by end of 2020
